Publications & Presentations

February 10, 2018

PresentationTivozanib

ASCO GU 2018: Tivozanib Combined With Nivolumab: Phase Ib/II Study in Metastatic Renal Cell Carcinoma

November 8, 2017

PublicationFiclatuzumab

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Gth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

Authors: Eng-Huat Tan, Wan-Teck Lim, Myung-Ju Ahn, Quan-Sing Ng, Jin Seok Ahn, Daniel Shao-Weng Tan, Jong-Mu Sun, May Han, Francis C. Payumo, Krista McKee, Wei Yin, Marc Credi, Shefali Agarwal, Jaroslaw Jac, Keunchil Park. Click here for link to article.

November 3, 2017

PresentationTivozanib

KCS 2017: TiNivo, A Phase Ib Dose Escalation Trial of Tivozanib and Nivolumab in Renal Cell Carcinoma

June 5, 2017

PresentationFiclatuzumab

ASCO 2017: Phase I study of the anti-HGF monoclonal antibody, ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer

June 5, 2017

PresentationFiclatuzumab

ASCO 2017: CyFi: A phase I study exploring the role of cMET pathway inhibition with ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)

June 4, 2017

PresentationTivozanib

ASCO 2017: Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)